NewAmsterdam Pharma Company NV
NAMS21.442USD
+0.162+0.76%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.41BValor de mercado
PerdaP/L TTM
Mais detalhes de NewAmsterdam Pharma Company NV Empresa
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Informações da empresa
Código da empresaNAMS
Nome da EmpresaNewAmsterdam Pharma Company NV
Data de listagemNov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
Número de funcionários68
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 23
EndereçoGooimeer 2-35
CidadeNAARDEN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísNetherlands
Código postal1411 DC
Telefone31352062971
Sitehttps://ir.newamsterdampharma.com/
Código da empresaNAMS
Data de listagemNov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Kling
Mr. Douglas Kling
Chief Operating Officer
Chief Operating Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 24 de jul
Atualizado em: qui, 24 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Frazier Life Sciences Management, L.P.
14.36%
Bain Capital Life Sciences Investors, LLC
9.55%
Forbion Capital Partners
9.49%
Capital Research Global Investors
9.26%
RA Capital Management, LP
9.03%
Other
48.31%
Investidores
Investidores
Proporção
Frazier Life Sciences Management, L.P.
14.36%
Bain Capital Life Sciences Investors, LLC
9.55%
Forbion Capital Partners
9.49%
Capital Research Global Investors
9.26%
RA Capital Management, LP
9.03%
Other
48.31%
Tipos de investidores
Investidores
Proporção
Investment Advisor
35.92%
Investment Advisor/Hedge Fund
23.68%
Venture Capital
21.76%
Private Equity
14.36%
Hedge Fund
13.18%
Research Firm
1.42%
Family Office
0.71%
Individual Investor
0.45%
Bank and Trust
0.28%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
262
128.82M
114.74%
+5.59M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
2023Q2
109
71.10M
86.48%
+7.09M
2023Q1
105
62.44M
76.40%
-1.21M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Frazier Life Sciences Management, L.P.
16.12M
14.36%
+200.00K
+1.26%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
10.72M
9.55%
--
--
Mar 31, 2025
Forbion Capital Partners
10.66M
9.49%
-279.14K
-2.55%
Apr 15, 2025
Capital Research Global Investors
8.83M
7.86%
--
--
May 31, 2025
RA Capital Management, LP
10.14M
9.03%
+1.29M
+14.63%
Mar 31, 2025
Viking Global Investors LP
6.98M
6.22%
--
--
Mar 31, 2025
Capital World Investors
6.80M
6.06%
+5.78M
+569.10%
Mar 31, 2025
Deerfield Management Company, L.P.
4.10M
3.66%
-210.38K
-4.88%
Mar 31, 2025
Wellington Management Company, LLP
3.54M
3.15%
+1.23M
+52.99%
Mar 31, 2025
Jennison Associates LLC
3.97M
3.54%
-28.35K
-0.71%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ALPS Medical Breakthroughs ETF
1.38%
Global X Guru Index ETF
1.17%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Invesco Dorsey Wright SmallCap Momentum ETF
0.35%
First Trust Small Cap Growth AlphaDEX Fund
0.29%
ProShares Ultra Nasdaq Biotechnology
0.23%
Invesco Nasdaq Biotechnology ETF
0.23%
iShares Biotechnology ETF
0.12%
First Trust Small Cap Core Alphadex Fund
0.11%
First Trust IPOX Europe Equity Opportunities ETF
0.09%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção1.38%
Global X Guru Index ETF
Proporção1.17%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.78%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0.35%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.29%
ProShares Ultra Nasdaq Biotechnology
Proporção0.23%
Invesco Nasdaq Biotechnology ETF
Proporção0.23%
iShares Biotechnology ETF
Proporção0.12%
First Trust Small Cap Core Alphadex Fund
Proporção0.11%
First Trust IPOX Europe Equity Opportunities ETF
Proporção0.09%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
